AG真人官方

STOCK TITAN

Lava Therapeutics Bv SEC Filings

LVTX NASDAQ

Welcome to our dedicated page for Lava Therapeutics Bv SEC filings (Ticker: LVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Decoding LVTX鈥檚 science-heavy disclosures shouldn鈥檛 require a PhD. Every LAVA Therapeutics SEC filing packs dense clinical data on its Gammabody庐 bispecific T-cell engagers, R&D spending, and cash runway鈥攄etails critical for judging immuno-oncology risk.

Our AI-powered platform turns those complex Form 20-F pages鈥攁nd the 6-K updates that follow each trial milestone鈥攊nto concise insights you can act on. Whether you search for 鈥渓ava therapeutics insider trading Form 4 transactions鈥� or 鈥渓ava therapeutics quarterly earnings report 10-Q filing,鈥� you鈥檒l land here and find:

  • AG真人官方-time Form 4 insider transactions with alerts that flag executive stock moves moments after they hit EDGAR.
  • Plain-English breakdowns of annual reports鈥攖hink 鈥渓ava therapeutics annual report 10-K simplified鈥濃攈ighlighting pipeline progress, collaboration revenue, and cash burn projections.
  • Side-by-side comparisons of each 6-K (8-K material events explained) so you can track dose-escalation data, FDA feedback, or new licensing deals without reading the full PDF.

Common questions are answered along the way: Where is LVTX鈥檚 proxy statement executive compensation? How do I read a lava therapeutics earnings report filing analysis? What does that shelf registration mean for dilution? Our AI extracts the numbers, footnotes, and trial endpoints that matter鈥攕aving hours while boosting confidence.

Stop searching multiple sources. Get every filing type鈥攆rom S-8 share plans to F-3 offerings鈥攑lus 鈥渦nderstanding lava therapeutics SEC documents with AI鈥� tutorials, all updated in real time. When fresh data shapes the future of gamma-delta T-cell therapy, you鈥檒l see it here first.

Rhea-AI Summary

LAVA Therapeutics is a clinical-stage immuno-oncology company focusing on its Gammabody platform. As of June 30, 2025, the company held $26.4 million in cash and $29.8 million of short-term U.S. Treasury investments ($56.2 million total), with and an accumulated deficit of $187.1 million. The company reported a $12.1 million net loss for the six months ended June 30, 2025 and generated $0 revenue in that period versus $7.0 million in the prior-year period (Pfizer milestone).

The board adopted a restructuring plan in February 2025 that reduced the workforce by ~30% and produced $3.2 million of restructuring and impairment charges year-to-date. Management recorded a $5.2 million non-cash gain when an RVO loan balance was waived. Subsequent events include a share purchase agreement with XOMA (tender offer price of $1.16 per share plus up to $0.08 and one CVR per share) and the decision to discontinue the Phase 1 LAVA-1266 program, with wind-down costs currently undetermined. The company states its cash and short-term investments are sufficient to fund operations for at least the next 12 months under current plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
tender offer
Rhea-AI Summary

On 3 Aug 2025, LAVA Therapeutics N.V. (NASDAQ: LVTX) signed a Share Purchase Agreement with XOMA Royalty Corp. Buyer will launch a tender offer within 10 business days to acquire 100 % of LVTX shares for a cash consideration of $1.16 per share plus up to $0.08 additional cash and one contingent value right (CVR) per share (together, the 鈥淥ffer Consideration鈥�). The CVR entitles holders to future cash payments linked to (i) post-closing net-cash adjustments, (ii) proceeds from any disposition of LAVA-1266 assets, and (iii) up to 75 % of collaboration proceeds with Pfizer and Johnson & Johnson for 10 years.

The Board has unanimously approved and recommends the Offer. Closing is subject to usual conditions, including 鈮�80 % (potentially 75 %) share tender, no legal injunctions, accuracy of representations, minimum net-cash, shareholder approvals and no material adverse effect; there is no financing condition. Buyer may extend the offer until 31 Dec 2025. If successful, a downstream Dutch merger will cancel untendered shares for the same consideration, delist LVTX from Nasdaq and terminate its SEC reporting. A $750 k termination fee is payable to XOMA under specified circumstances.

Separately, LVTX disclosed the discontinuation of its Phase 1 LAVA-1266 program for AML/MDS. A press release announcing the transaction was issued on 4 Aug 2025 (Exhibit 99.1).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Lava Therapeutics Bv (LVTX)?

The current stock price of Lava Therapeutics Bv (LVTX) is $1.53 as of August 13, 2025.

What is the market cap of Lava Therapeutics Bv (LVTX)?

The market cap of Lava Therapeutics Bv (LVTX) is approximately 40.0M.
Lava Therapeutics Bv

NASDAQ:LVTX

LVTX Rankings

LVTX Stock Data

39.98M
17.71M
32.69%
36.96%
0.2%
Biotechnology
Pharmaceutical Preparations
Netherlands
UTRECHT